沙利度胺联合LD-Arac治疗高危骨髓增生异常综合征27例

Thalidomide and Low-Arac Treatment for 27 cases with High Risk Myelodysplastic Syndromeombination

目的观察沙利度胺及小剂量阿糖胞苷(LD-Arac)治疗高危骨髓增生异常综合征的疗效,研究高危MDS的治疗方法。方法对27例高危骨髓增生异常综合征患者,应用LD-Arac10～15mg/m2,每12h1次皮下注射,15～21天1疗程,间隔10～15天重复。沙利度胺100mg·d-1,早、晚2次口服,无严重副作用者每周递增50mg·d-1,最大剂量300mg·d-1。结果完全缓解12例(44%),部分缓解6例(22%),3例进步,6例无效,总有效率66%。9例(33%)在治疗中转化为急性白血病。结论LD-Arac和沙利度胺治疗高危MDS确有明显疗效,无严重骨髓抑制,无感染及出血,明显改善高危MDS病人的预后。

Objective To obserye the effects of Thalidomide andLD-Arac therapy in High Risk Myelodysplastic Syndromeombination(MDS));Methods 27 MDS patients were treated by Thalidomide and LD-Arac.Arac10～15mg/m2 were given by hypodermic injection every12 hours for15～21days and repeated after 10～15 days,Thalidomide were given by po 100mg·d-1,and twice a day. They were increased 50mg·d-1 every week for no serious side effect, s patients and the most dose was 300mg·d-1. Results 12 cases had got complete remission (CR)(44%),4 cases partial remission (PR)(22%),3 cases improved,and 6 cases ineffective .Total effective rate was 66%.9 cases tuened intoAML.Conclusion The results show that LD-Arac and Thalidomide therapy, no serious bone marrow refrain and no infection and bleeding,is an effective method in improveing the patient prognosis.